It has been previously documented for different breast cancer cell lines that sulforapahane downregulates ER-α, EGFR and HER2 proteins [49] as well as PI3K-Akt-mTOR signaling pathway [45] whose overactivity may contribute to resistance of ER-positive cancers to endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.